跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 591 条关于
“CIAS”
全部
591
临床试验
487
药物
54
机构
4
资讯
46
去年
Atai Life Sciences' Schizophrenia Cognitive Drug Inidascamine Fails Primary Endpoint in Phase 2 Trial
上个月
Kynexis Extends Series A to €97 Million to Advance First-in-Class KAT-II Inhibitor for Cognitive Impairment in Schizophrenia
5个月前
Two Phase 2 Trials Fail to Demonstrate Cognitive Benefits in Schizophrenia Despite Different Mechanisms
11个月前
Kynexis Initiates Phase 2 Trial of First-in-Class KAT-II Inhibitor for Schizophrenia-Associated Cognitive Impairment
去年
Cambridge Cognition Advances Digital Assessment Tool for Schizophrenia-Related Cognitive Impairment
去年
Monument Therapeutics Reports Positive Phase I Results for Novel Schizophrenia Cognitive Treatment MT1988
去年
Recognify's Inidascamine Misses Primary Endpoint in Phase 2b Trial for Schizophrenia-Associated Cognitive Impairment
2年前
ATAI Life Sciences Reports Positive Q3 2023 Financials and Advances Clinical Pipeline
去年
Monument Therapeutics Raises £850K to Advance Novel Schizophrenia Cognitive Treatment MT1988
去年
Major Pipeline Expansion in Schizophrenia Treatment: 55+ Companies Developing 60+ Novel Therapies
第 1 页,共 5 页
上一页
下一页